Taking into account TNF-α expression as an important factor in antitumoral response, a clinical study on triple-negative breast cancer (TNBC) used TNF-α expression profiles as a biomarker to evaluate patients’ response to LCL161 and paclitaxel. This evidence concerns the gene TNF and triple-negative breast carcinoma.